Newsletter
Sign Up And Receive Our Latest Promotions!
Thank you! Your submission has been received!
.svg){kind=small}
Real world evidence insights
coming soon in Q4'2023 to transform Data-Driven decisions
Together with Retina Consultants of America, we are collaborating to build the most comprehensive Real World Evidence (RWE) insights in Ophthalmology. We will combine clinical and imaging data with AI-driven biomarker and endpoint measures to provide an in-depth understanding to retinal diseases such as Age-related Macular Degeneration (AMD) - including intermediate AMD (iAMD), Geographic Atrophy (GA), neovascular AMD (nAMD) - as well as insights into Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and other retinal disease.
Benefits of accessing Real World Evidence Insights
Research and Development
- Improve clinical study design
- Optimize therapeutic target selection
- Accelerate time to market
.png)
Medical and Commercial
- Enable pharmacovigilance strategies
- Improve targeting of commercial activities
- Generate evidence of economis value
.png)
Novel Opportunities
- Opportunities to develop precision-based medicine or diagnostics
Find out more about collaboration with RCA
.png)
Retina Consultants of America
RetinAI Medical AG and Retina Consultants of America (RCA)
forge a strategic partnership to revolutionize Ophthalmology data.
Leveraging RetinAI's advanced AI technologies and RCA's
expansive clinic network, this alliance is set to develop
the largest Real World Evidence (RWE)
U.S.-based database in the field.
Learn more >
forge a strategic partnership to revolutionize Ophthalmology data.
Leveraging RetinAI's advanced AI technologies and RCA's
expansive clinic network, this alliance is set to develop
the largest Real World Evidence (RWE)
U.S.-based database in the field.
Learn more >
*Disclaimer
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.
